The Indian drugmaker unveiled the new capacity at its facility in Mirfield, England this week, explaining that the enable it produce 'metric tonne scale quantities' of its PEGtech - methyl ether polyethylene glycol (mPEG) - range of conjugation technologies.
Dr Reddy's claims its PEGtech business is used by a wide range of developers - from biotechs to large biopharmas - seeking to "improve the stability and the pharmaco-kinetic properties of biologic drugs."
Early R&D services are provided at its subsidiary Chirotech - also located in the UK at a site in Cambridge - and the expansion establishes Mirfield as the scale-up ad commercial production facility.
R. Ananthanarayanan, president of the Indian firm's pharma services business, made reference to the firm's efforts to grow in the UK.
“This expansion builds on our commitment to expand operations in UK and provide a superior network of cGMP manufacturing to support our global customer base. PEGylation is one area where we felt the need for expanding our capabilities."
Dr Reddy's has also added active pharmaceutical ingredient (API) production capacity at Mirfield for batch sizes for preclinical development, scale-up and commercial production.
The investment means the Indian generic drugmaker now has eight API fully operational production plants after the US FDA lifted an import ban it imposed in the firm's facility in Mexico in July .
At the time Dr Reddy's said: "With the satisfactory closure of observations in the warning Letter and the lifting of the import alert, Dr. Reddy's can now start importing products to the US from this facility.